Start free

Nuo Therapeutics, Inc. (AURX) insider trading

Recent insider transactions reported to the SEC on Form 4 — directors and officers buying or selling their own company’s stock. Sourced directly from public SEC filings, latest filed Oct 6, 2026.

Filings shown
10
Open-market buys
2
Open-market sells
0
Buys, 10b5-1 box not checked
2 of 2

Counts cover the 10 most recent Form 4 filings Tradune holds for AURX (filed Jun 2 – Oct 6, 2026); the score below covers only the trailing 90 days (0 buys, 0 sells). SEC EDGAR Form 4 filings for AURX last checked Nov 22, 2026, 09:00 UTC; the latest AURX filing Tradune holds was filed Oct 6, 2026. This is not guaranteed to be the complete record — see AURX's full Form 4 filing history on SEC EDGAR.

Open-market activity, last 90 days

Purchases (Form 4 code P) and sales (code S) on the 2 filings Tradune holds for AURX filed Aug 31 – Oct 6, 2026. Grants, exercises, tax withholding and the other Form 4 transaction codes are left out.

Open-market purchases and sales by insider
Insider Buys Sells Shares bought Shares sold Value
David Emerson JordenCEO/CFO 2 0 8,773 — +$9,539

Value = shares × the price reported on each Form 4 (+ purchases, − sales); every open-market line in this window disclosed a price.

Insider-activity score

0/ 100

No notable activity
0 distinct buyers0 buy · 0 sell tx

Summarises ~90 days of public SEC Form 4 activity — more distinct buyers, officer involvement and net buying score higher. A description of filing activity, not a rating or buy signal. How this score is computed →

Get alerted when insiders buy the stocks you own

Add your holdings — no brokerage login — and Insider Radar sends a Telegram alert when an open-market Form 4 buy of $100,000 or more is filed on a stock you hold or watch.

Free for everyone right now · no card · nothing to buy

Start free

How to read this: an open-market purchase (Form 4 code P) is a buy at the market price with the insider’s own money, as opposed to a grant, award or option exercise; an open-market sale is code S. When two or more distinct insiders report open-market purchases in the same 90-day window, this site labels that a cluster — a definition, not a forecast; see insider cluster buying. “Held after” is Form 4 Table I column 5; “Change” = shares ÷ holdings before the trade (held after − shares for an acquisition, held after + shares for a disposition).

Insider Buying at AURX

Insiders reported 2 open-market purchases of AURX between Jun 2, 2026 and Oct 6, 2026, across 1 distinct buyer. The most recent purchase was reported by David Emerson Jorden (CEO/CFO) on Aug 28, 2026. Grants, option exercises, and tax-withholding transactions are excluded from these counts.

Recent Form 4 filings

Source: SEC EDGAR Form 4 · transaction codes explained

Scott M. Pittman Director, 10% owner · filed Oct 6, 2026 · SEC ↗
TransactionSharesPriceHeld afterChange†Date
Grant / award Prepayment Restated Warrant (right to buy) 458 $1.50 — — Oct 6, 2026
Grant / award Second Restated Warrant (right to buy) 4,500 $1.50 — — Oct 6, 2026
David Emerson Jorden amended CEO/CFO · filed Aug 31, 2026 · SEC ↗
TransactionSharesPriceHeld afterChange†Date
Open-market purchase 10b5-1 box not checked 7,984 $1.09 2,070,000 +0.4% Aug 28, 2026
Open-market purchase 10b5-1 box not checked 789 $1.07 2,062,016 +0.0% Aug 27, 2026

† change in this filer’s own reported holding line (Form 4 Table I, col. 5), not of total company ownership; small prior holdings produce large percentages, so under 100 shares the prior holding is shown instead.

“10b5-1 box checked” = the filer checked the Form 4 box stating that a transaction on the filing was made under a plan intended to satisfy Rule 10b5-1(c); “10b5-1 box not checked” = the box was left blank, which does not prove that no plan exists. The box applies to Form 4s filed from April 1, 2023; older filings, and boxes we could not read, carry no tag. What the 10b5-1 box means.

David Emerson Jorden CEO/CFO · filed Jul 2, 2026 · SEC ↗
TransactionSharesPriceHeld afterChange†Date
Option exercise 162,500 $1.00 2,222,119 +7.9% Jun 30, 2026
Option exercise Option to purchase common stock 162,500 — — — Jun 30, 2026
Tax withholding 160,892 $1.01 2,061,227 −7.2% Jun 30, 2026
Grant / award Option to purchase common stock 125,000 — — — Jun 29, 2026
Scott M. Pittman Director, 10% owner · filed Jul 2, 2026 · SEC ↗
TransactionSharesPriceHeld afterChange†Date
Option exercise Option to purchase common stock 40,000 — — — Jun 30, 2026
Tax withholding 39,604 $1.01 5,400,396 −0.7% Jun 30, 2026
Option exercise 40,000 $1.00 5,440,000 +0.7% Jun 30, 2026
Grant / award Option to purchase common stock 30,000 — — — Jun 29, 2026
C. Eric Winzer Director · filed Jul 2, 2026 · SEC ↗
TransactionSharesPriceHeld afterChange†Date
Option exercise 40,000 $1.00 212,654 +23% Jun 30, 2026
Tax withholding 39,604 $1.01 173,050 −19% Jun 30, 2026
Option exercise Option to purchase common stock 40,000 — — — Jun 30, 2026
Grant / award Option to purchase common stock 30,000 — — — Jun 29, 2026
Peter Clausen CSO/COO · filed Jul 2, 2026 · SEC ↗
TransactionSharesPriceHeld afterChange†Date
Grant / award Option to purchase common stock 65,000 — — — Jun 29, 2026
Paul Mintz Director · filed Jul 2, 2026 · SEC ↗
TransactionSharesPriceHeld afterChange†Date
Grant / award Option to Purchase Common Stock 30,000 — — — Jun 29, 2026
David Emerson Jorden CEO/CFO · filed Jun 5, 2026 · SEC ↗
TransactionSharesPriceHeld afterChange†Date
Grant / award 13,245 $1.10 2,085,000 +0.6% Jun 5, 2026
Scott M. Pittman Director, 10% owner · filed Jun 2, 2026 · SEC ↗
TransactionSharesPriceHeld afterChange†Date
Grant / award Second Restated Warrant (right to buy) 17,500 $1.50 — — May 29, 2026
Disposition to issuer Prepayment Warrant (right to buy) 7,516 $1.50 — — May 29, 2026
Grant / award Prepayment Restated Warrant (right to buy) 7,333 $1.50 — — May 29, 2026
Disposition to issuer Second Warrant (right to buy) 36,750 $1.50 — — May 29, 2026
Grant / award Interim Warrant (right to buy) 17,450 $1.50 — — May 29, 2026
Scott M. Pittman amended Director, 10% owner · filed Jun 2, 2026 · SEC ↗
TransactionSharesPriceHeld afterChange†Date
Grant / award Initial Warrant (right to buy) 30,050 $1.50 — — Jan 23, 2026
Grant / award Second Warrant (right to buy) 36,750 $1.50 — — Jan 23, 2026
Grant / award Prepayment Warrant (right to buy) 7,516 $1.50 — — Jan 23, 2026

Insider filings reported around the same time

Other companies whose most recent Form 4 was filed closest to AURX's (Oct 6, 2026).

Frequently asked about AURX insider activity

How many insiders bought AURX stock in these Form 4 filings?

1 distinct insider at Nuo Therapeutics, Inc. reported 2 open-market purchases (Form 4 code P) of AURX shares between Jun 2, 2026 and Oct 6, 2026, the most recent filed by David Emerson Jorden (CEO/CFO) on Aug 28, 2026. Grants, option exercises, and tax-withholding transactions are excluded from these counts.

Who filed the most recent Form 4 for AURX?

The most recent Form 4 on this page was filed by Scott M. Pittman (Director, 10% owner) on Oct 6, 2026, reporting 2 transactions. The original document is linked from the filing list above on SEC EDGAR. Amended filings (Form 4/A) may later revise reported figures.

What was the largest open-market AURX insider purchase shown?

The largest open-market purchase among the filings shown was 7,984 AURX shares at $1.09 (about $8,695) by David Emerson Jorden (CEO/CFO) on Aug 28, 2026. Value is shares × the price reported on the Form 4; its Rule 10b5-1 box is not checked.

Do the recent AURX insider purchases have the Form 4 10b5-1 box checked?

No. All 2 AURX open-market purchases shown were reported with the Rule 10b5-1 box not checked. A blank box records what the filer disclosed; it does not prove that no plan exists. Latest: David Emerson Jorden (CEO/CFO) on Aug 28, 2026, 7,984 shares.

New to Form 4s? The transaction codes, the 90-day window and the 0–100 score are defined on the insider-activity score methodology page.

Get insider alerts for AURX — and your whole portfolio

Tradune watches SEC Form 4 filings and flags insider-cluster buying across everything you hold, routed to you automatically. Free for everyone right now · no card · nothing to buy

This score summarizes SEC Form 4 filing activity over the trailing 90 days. It is descriptive, not predictive — not a rating, recommendation, or investment advice. Data: SEC EDGAR (public domain), as filed; amendments may revise figures. Tradune is not a registered investment adviser.

Data as filed; amended filings (Form 4/A) may revise figures. Sales may occur under prearranged Rule 10b5-1 trading plans.